Tue. 2 Apr 2024, 7:10am ET
Benzinga
M&A, News
Today, Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of Modulus Therapeutics' cell therapy platform assets, including their chimeric antigen receptor (CAR) and switch receptor libraries.